Capital Research Global Investors Sells 1,083,633 Shares of Gilead Sciences, Inc. $GILD

Capital Research Global Investors cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,014,046 shares of the biopharmaceutical company’s stock after selling 1,083,633 shares during the period. Capital Research Global Investors’ holdings in Gilead Sciences were worth $3,331,573,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the third quarter worth about $26,000. Howard Hughes Medical Institute acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at about $30,000. MTM Investment Management LLC raised its stake in shares of Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 176 shares in the last quarter. Kilter Group LLC bought a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $33,000. Finally, Millstone Evans Group LLC lifted its holdings in Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 118 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 1.9%

NASDAQ GILD opened at $146.63 on Tuesday. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock’s 50 day moving average is $138.73 and its two-hundred day moving average is $126.06. The company has a market capitalization of $182.03 billion, a price-to-earnings ratio of 21.66, a PEG ratio of 1.89 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the previous year, the firm earned $1.90 EPS. Gilead Sciences’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is currently 46.68%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the sale, the chief financial officer owned 167,779 shares in the company, valued at $25,910,110.97. This trade represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 309,280 shares of company stock worth $43,935,470. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on GILD shares. Royal Bank Of Canada upped their target price on Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 11th. Citigroup restated a “buy” rating on shares of Gilead Sciences in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Finally, Scotiabank raised their price target on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $156.72.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.